About Us : RCMG Inc. | The Development of novel glycobiomarker/IVD

RCMG Inc. is a technology-based company and we KNOW HOW to detect “differences” specific to disease conditions suitable for the diversity of personalized medicine.

Overview

RCMG Inc. was founded by Dr. Narimatsu*, a pioneer of establishing various technologies of glycoscience research over 35-years with great success, intellectual properties and know-how. Dr. Angata*, co-founder and CEO of RCMG Inc, has research experience in glycobiology over 25-years.
RCMG’s proprietary technology platform is able to continually create novel biomarkers/in vitro diagnostics (IVDs) to detect specific disease conditions suitable for the diversity of personalized medicine.

Aim of RCMG Inc. is to contribute to human health care by using glycotechnology that we studied and developed. Glycan is the fourth life chain in the biology field, which is our target molecule presenting differences in cells, organs, and individuals.
Current IVD pipeline includes inflammation, infectious disease, and oncology. Since glycosylation of cellular surfaces and secreted proteins reflects conditions of cells in patients, suffering from infections or cancers, glyco-biomarkers for specific diseases would create more accurate biomarkers.
> Project Page

RCMG’s pharmaco-glycoproteomics is able to stratify individual samples in view of drug response. Pharmaco-glycoproteomics would contribute to obtain early signal efficacy of new drug in the development, stratify patient subpopulation and determine effective inclusion/exclusion criteria prior to large clinical trial for pharmaceutical companies.

　Company Infomation:

　Company name

RCMG Inc.

　Address

2-1-6 Sengen, Plaza Suite 106, Tsukuba, Ibaraki 305-0047
TEL：+81-29-828-8010

　CEO

Kiyohiko Angata, Ph.D.

　Business

Development of novel glycobiomarker/IVD.

Dr. Hisashi Narimatsu, MD and Ph.D. (Chair of the board)

Profile

Dr. Narimatsu graduated from the School of Medicine and Graduate School of Medicine at Keio University where he received his MD and PhD, respectively. At U.S. National Institutes of Health (NIH), he successfully cloned the first glycosyltransferase, b1,4galactosyltransferase. After he joined AIST and led 10 national projects for the development and application of glycotechnologies, dedicating to facilitate the glycoscience.

Past Appointments

Professor at the Soka University
Director of Research Center for Medical Glycoscience at the National Institute of Advanced Industrial Science and Technology (AIST)
Adjunct Professor at the University of Tsukuba
Advisory Professor at the Shanghai Jiao Tong University (PRC)
CEO of RCMG Inc.

Dr. Kiyohiko Angata, Ph.D. (CEO)

Profile

Dr. Angata received PhD degree from the Graduate School of University of Tsukuba. He studied glycobiology at the La Jolla Cancer Research Foundation (presently the Sanford Burnham Prebys Medical Discovery Institute). He joined AIST led by Dr. Narimatsu, and participated in 4 national projects including HBV, Glycomedicine, and Database.

Past Appointments

Staff Scientist at the Burnham Institute for Medical Research (USA)
Invited Researcher at the AIST
Head of R&D at the RCMG Inc.

RCMG Inc.

2-1-6 Sengen, Plaza Suite 106, Tsukuba, Ibaraki 305-0047
TEL：+81-29-828-8010

Service

Home
About Us
Products & Services
Research Products
Contract Services
Projects
Latest News
News
Access
Contact
Japanese Website